Statistical design of Path to Prevention platform trial in early neuronal alpha-synuclein disease

The Path to Prevention (P2P) platform trial is a first-in-class, phase 2A, randomized, double-blind, placebo-controlled learning study. Its design expedites the assessment of investigational therapies for the treatment of early-stage Neuronal a-Synuclein Disease (NSD), a biological disease continuum that encompasses and often precedes clinically manifest Parkinson's Disease. P2P is embedded within the Parkinson's Precision Medicine Initiative (PPMI), a robust observational longitudinal cohort study on Parkinson's disease progression and a trial-facilitating enrollment framework. A regimen, com

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.